NITRO Drug Patent Profile
✉ Email this page to a colleague
When do Nitro patents expire, and when can generic versions of Nitro launch?
Nitro is a drug marketed by Pohl Boskamp, Sanofi Aventis Us, Uspharma, Actavis Labs Fl Inc, Alembic, Aurobindo Pharma Usa, Impax Labs Inc, Mankind Pharma, Novel Labs Inc, Pom Pharma, Sun Pharm Industries, Watson Labs, Zydus Pharms, Actavis Mid Atlantic, Amneal Pharms, Annora Pharma, Aurobindo Pharma, Biocon Pharma, Novitium Pharma, Somerset Theraps Llc, Strides Pharma, Elkins Sinn, Ivax Sub Teva Pharms, Sandoz, Whiteworth Town Plsn, Alvogen, Chartwell Rx, Creekwood Pharms, Inventia, Omsav Pharma, Ranbaxy Labs Ltd, Sunny, Watson Labs Inc, Ambix, Lannett, Perrigo New York, Sun Pharma Canada, Wendt, Lannett Co Inc, Mylan Technologies, Abraxis Pharm, Am Regent, Hospira, Intl Medication, Luitpold, Smith And Nephew, Cosette, Encube, Solaris Pharma Corp, Tp Anda Holdings, Fougera Pharms Inc, Padagis Israel, Dr Reddys, Glenmark Speclt, Natco, Rubicon Research, Sigmapharm Labs Llc, Viwit Pharm, Baxter Hlthcare, Rorer, Evus, Abbott, Abbvie, Vpna, Parke Davis, and Viatris. and is included in one hundred and two NDAs. There is one patent protecting this drug.
The generic ingredient in NITRO is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nitro
A generic version of NITRO was approved as sodium nitroprusside by SAGENT PHARMS INC on December 8th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NITRO?
- What are the global sales for NITRO?
- What is Average Wholesale Price for NITRO?
Summary for NITRO
| US Patents: | 0 |
| Applicants: | 66 |
| NDAs: | 102 |
| Drug Prices: | Drug price information for NITRO |
| Drug Sales Revenues: | Drug sales revenues for NITRO |
| DailyMed Link: | NITRO at DailyMed |
US Patents and Regulatory Information for NITRO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | NITROFURANTOIN MACROCRYSTALLINE | nitrofurantoin, macrocrystalline | CAPSULE;ORAL | 070248-001 | Jun 24, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Smith And Nephew | NITROGLYCERIN | nitroglycerin | INJECTABLE;INJECTION | 070633-001 | Jun 19, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Amneal Pharms | NITROFURANTOIN | nitrofurantoin | SUSPENSION;ORAL | 201679-001 | May 11, 2011 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm Industries | NITROFURANTOIN | nitrofurantoin, macrocrystalline | CAPSULE;ORAL | 201722-003 | Feb 16, 2016 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Parke Davis | NITROSTAT | nitroglycerin | INJECTABLE;INJECTION | 018588-002 | Dec 23, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
